IngredientsAntibodies — also called immunoglobulins — are glycoproteins that bind antigens with high specificity and affinity. In humans there are five chemically and physically distinct classes of antibodies (IgG, IgA, IgM, IgD, and IgE). Immunoglobulin G (IgG) is the most abundant type of antibody, found in all body fluids, and protects against bacterial and viral infections. IgG represents approximately 75% of serum antibodies in humans and is the most common type of antibody found in the circulation, with a serum concentration of 10 to 16 mg/mL; it is also considered the major immunoglobulin in extravascular spaces.
As a dietary supplement, IgG is most commonly encountered as a concentrated protein fraction isolated from animal sources — principally bovine (cattle) serum or colostrum — and is variously referred to as bovine immunoglobulin G, serum-derived bovine immunoglobulin/protein isolate (SBI), bovine colostrum IgG, or plasma-derived immunoglobulin, depending on the source and processing method.
IgG antibodies are large molecules with a molecular weight of approximately 150 kDa, composed of two different kinds of polypeptide chain: one of approximately 50 kDa termed the heavy (H) chain, and the other of 25 kDa termed the light (L) chain. The resulting tetrameric quaternary structure has a total molecular weight of about 150 kDa. The two heavy chains are linked to each other and to a light chain each by disulfide bonds. The resulting tetramer has two identical halves, which together form a Y-like shape. Each end of the fork contains an identical antigen-binding site. The Fc regions of IgGs bear a highly conserved N-glycosylation site at asparagine 297 in the constant region of the heavy chain. The N-glycans attached to this site are predominantly core-fucosylated biantennary structures of the complex type.
IgG is the most abundant class of antibody in the colostrum and milk of several mammalian species, comprising 80–90% of total antibodies. The primary structure of IgG contains two heavy chains (each of 450–550 amino acids) and two light chains (each of 211–217 amino acids) with a total molecular mass of approximately 150–160 kDa and a pI of 5.5–8.3.
There are four subclasses of IgG: IgG1, IgG2, IgG3, and IgG4, which are differentiated on the basis of the position of interchain disulfide bonds, the size of the hinge region and molecular weight, as well as antigenic differences in the structure of the heavy chain. The numeric designations of the subclasses correspond to the order of their proportional amounts in healthy adult serum: IgG1 > IgG2 > IgG3 > IgG4. IgG1 comprises 60 to 65% of the total IgG and is usually produced in response to protein antigens which are T-dependent antigens. IgG2 comprises 20 to 25% of the total IgG and is the prevalent immune response against carbohydrate/polysaccharide antigens. IgG3 comprises around 5 to 10% of total IgG and plays a major role in the immune response against protein or polypeptide antigens.
IgG is also the principal antibody and predominant immunoglobulin of bovine colostrum. Bovine IgG occurs in two subclasses: IgG1 and IgG2.
The immunoprotective properties of bovine milk immunoglobulin G (IgG) have led to a recent proliferation of nutritional products incorporating this protein. As a dietary supplement, IgG is derived from two principal animal sources:
Studies on the effect of bovine immunoglobulins on human immune function and susceptibility to infection have been performed with a wide range of immunoglobulin-rich products, which can be categorized into three groups: IgG-isolates from colostrum or milk, IgG-rich colostrum, and serum-derived IgG.
Common commercial preparations include whole bovine colostrum powder (typically standardized to a specified IgG percentage), IgG-enriched colostrum fractions, and purified serum-derived protein isolates. Standardization of commercial bovine colostrum products is difficult because antibody content varies widely. Products are typically sold in powder (bulk or individual sachets), capsule, or tablet form.
The use of colostrum to treat illnesses and to contribute to well-being dates from thousands of years ago. In India, Ayurvedic physicians prescribed colostrum throughout thousands of years, and colostrum still very often represents the first medicine used by many families. The use of colostrum for both medicinal and spiritual purposes has been documented in traditional Ayurvedic medicine and among the ancient Hindu rishis (spiritual leaders) of India. Their vital uses in the treatment of eye infections and to irrigate the eyes with bovine colostrum have been reported in the Indian system of Ayurveda.
In ancient Egypt, colostrum was regarded as a potent elixir with the ability to enhance physical strength and promote healing, aligning with the Egyptians' broader reverence for natural remedies.
At the turn of the 20th century, the use of colostrum was advocated to protect infants against both human and bovine infections. Prior to the advent of sulfa drugs and other antibiotics, colostrum was used to boost defense against immune diseases. Albert Sabin isolated antipolio antibodies in bovine colostrum in the 1950s; the first experiments with hyperimmune colostrum were conducted in the 1960s.
Oral immunoglobulin preparations are prime examples of medicinal nutrition from natural sources. Plasma products containing immunoglobulins have been used for decades in animal feed for intestinal disorders to mitigate the damaging effects of early weaning, reducing overall mortality and increasing feed utilization in various animal species, leading to improved growth.
Serum-derived bovine immunoglobulin isolate (SBI) is a specific concentrated serum protein fraction rich in immunoglobulins, particularly IgG. In colostrum-based preparations, colostrum contains immunoglobulins (IgG, IgA, and IgM), polypeptides and glycoproteins, lactoferrin, cytokines (including interleukins, interferon-gamma, and tumor necrosis factor alpha), and lactoperoxidase.
IgG is a monomer with an approximate molecular weight of 146 kDa and a serum concentration of 9.0 mg/mL. IgG is divalent — it has two identical antigen-binding sites that comprise 2 light chains and 2 heavy chains joined by disulfide bonds. IgG is synthesized mostly in the secondary immune response to pathogens, and can activate the classical pathway of the complement system.
Bovine colostrum is produced by healthy mammary glands until the first 72 hours postpartum, after which it acquires the typical physicochemical, microbiological, nutritional and rheological characteristics of milk. Colostrum is composed of unique bioactive compounds, which are divided into two main classes: immunological factors and growth factors. Beyond IgG, the immunological fraction includes other immunoglobulin isotypes (IgA, IgM), while growth factors such as IGF-1 and IGF-2 are also present and may contribute to certain observed effects, particularly in athletic performance and gut repair contexts. In serum-derived isolates (SBI), the preparation also includes transferrin, albumin, and alpha and beta serum proteins, with bovine IgG representing the predominant component.
IgG plays key roles in neutralizing pathogens, activating complement, promoting phagocytosis, and crossing the placenta via the neonatal Fc receptor (FcRn). When administered orally, the primary proposed mechanism of action of bovine IgG is intraluminal binding to microbial antigens and toxins within the gastrointestinal tract rather than systemic circulation. Serum-derived bovine immunoglobulin (SBI) prevents translocation and inflammation via direct binding of microbial components. Animal model experiments demonstrate that the immunoglobulins present in SBI neutralize LPS and other bacterial antigens and improve intestinal barrier function damaged by bacterial toxins.
Nonclinical studies have found that as much as 50% of IgG from SBI survives transit through the stomach, while 5–10% survives during transit through the entire intestinal tract. In a human study of SBI tolerability and digestion, intact bovine IgG was detected in the feces of volunteers but not serum (n=12), providing evidence that bovine immunoglobulin is not absorbed from the intestinal lumen into the circulation. Elevated plasma levels of total amino acids and leucine were observed 1–2 hours after SBI administration, suggesting at least partial digestion of the protein mixture to the amino acid level during transit through the intestine.
It is generally understood that IgG can only bind to antigens within the GI tract if the Fab structure is intact and has not been completely denatured through acidic pH or digestive proteolytic enzymes. This oral immunoglobulin undergoes reversible conformational changes under gastric pH and otherwise passes through the intestines unabsorbed.
Serum-derived bovine immunoglobulin/protein isolate (SBI) is believed to have a positive effect on GI mucosal barrier integrity by decreasing intestinal permeability, decreasing intestinal inflammation, and optimizing nutrient absorption. At human equivalent doses of 2 and 5 g/day, SBI significantly promoted gut barrier integrity and did so more profoundly than a dietary protein control, especially upon LPS-induced inflammation. SBI also specifically lowered inflammatory markers TNF-α and CXCL10.
In the intestine of suckling rodents and in the human placenta, the MHC class I–related Fc-receptor for IgG (FcRn) mediates transport of IgG across epithelial barriers by transcytosis. Transepithelial transport by FcRn explains how humoral immunity transfers from mother to infant. In contrast to rodents after weaning, absorptive epithelial cells lining the intestine of humans continue to express FcRn in adult life, and when tested in vitro, human, canine, and rodent epithelial cells in culture that express FcRn exhibit FcRn-dependent transcytosis of IgG in both directions across the epithelial monolayer. Based on these data, it has been proposed that FcRn may function in the adult human to shuttle IgG or IgG-antigen complexes across epithelial barriers for immune surveillance, host defense, or both.
In human intestine, there is an increasing proximal-distal gradient of mucosal FcRn mRNA and protein expression. This gradient suggests that the ileum and proximal colon may represent a physiologically relevant site where orally administered IgG can interact with the mucosal immune system.
SBI has also displayed potential benefits through gut microbiome modulation. SBI prevents translocation and inflammation via direct binding of microbial components and recently showed potential benefits through gut microbiome modulation. Both SBI and the reference prebiotic inulin enhanced short-chain fatty acids (acetate, propionate, and butyrate) via specific gut microbes, while SBI specifically stimulated valerate, branched-chain fatty acids, and indole-3-propionic acid. These effects are preliminary and require confirmation in controlled human clinical trials.
Oral SBI has been shown in clinical studies to reduce loose stools and improve stool consistency as well as other symptoms (i.e., abdominal pain, bloating, and urgency) in patients with IBS-D and HIV-associated enteropathy.
Wilson et al. (2013), in a pilot comparator-controlled trial of 6 weeks duration using 10 g/day soy protein isolate as comparator, found that either 10 g/day or 5 g/day of SBI in 30 patients resulted in statistically significant within-group improvements in daily symptom scores (e.g., urgency, flatulence, and abdominal pain) in subjects with IBS-D; however, there was no significant benefit over the comparator in this pilot study. Study subjects consuming SBI reported a significant decrease in the number of days with GI symptoms (e.g., abdominal pain, flatulence, bloating, urgency, and loose stools). Soy protein administered at the same dose did not statistically improve any GI symptoms.
A case series reported the outcomes of 14 IBS patients who received SBI as an addition to standard of care at an individual physician's clinical practice. For patients with IBS-M, there was some potential for efficacy during bouts of diarrhea and reduction in bloating, but the results suggested some mixed outcomes. Because of the alternating nature of symptoms in IBS-M patients, this population is often difficult to manage. In patients with IBS-C, the results were inconclusive and more data are needed to draw any final conclusions.
Evidence assessment: Evidence for IBS-D is preliminary. The available data come from small-scale, open-label, or comparator-controlled (rather than placebo-controlled) trials. No large, randomized, double-blind, placebo-controlled trials have been published to date, and the studies generally lack sufficient statistical power to establish efficacy definitively.
An open-label trial was conducted to examine the impact of SBI on restoration of mucosal immunity and gastrointestinal function in individuals with HIV enteropathy. The study used an intensive 8-week phase of bovine serum immunoglobulin 2.5 g twice daily with a 4-week washout period and an optional 9-month extension. HIV enteropathy was defined as chronic gastrointestinal symptoms including frequent loose or watery stools despite no identifiable, reversible cause. In a study where 8 patients were enrolled and received 5 g of SBI/day for 8 weeks followed by a 4-week washout period, administration of SBI led to consistent improvement in GI symptoms associated with HIV enteropathy. After 8 weeks of SBI administration, bowel movements per day decreased from 5.8.
In a study of colostrum supplementation on HIV-associated diarrhoea, 45 patients received 50 g of a commercially available colostrum-based food product twice daily for 28 days. There was a significant decrease of 79% in evacuation frequency in patients on the colostrum-based supplement at week 4, compared to a 58% decrease in the placebo group. The reduction in evacuation frequency was maintained five weeks after stopping supplementation, followed by significant weight gain.
Evidence assessment: Evidence is preliminary. Available clinical data consist primarily of small open-label trials and case reports. Larger controlled trials are needed to confirm efficacy in this population.
Several clinical trials suggest that hyperimmune bovine colostrum, prepared by immunizing cows with the causative agent, is effective in treating diarrhea caused by rotavirus, E. coli, and Cryptosporidium parvum.
One of the most extensively studied applications of bovine colostrum-derived IgG is the treatment of gut infections in children, including rotavirus, enteropathogenic and enterotoxigenic E. coli, Shigella, and Helicobacter pylori infections. Most of these studies have been conducted using hyperimmune bovine colostrum, which is produced by immunizing cows with select pathogens or toxins prior to lactation, with the intention of obtaining colostrum with enriched titers of pathogen-specific IgG antibodies.
Consuming three daily servings of 100 mL of hyperimmune bovine colostrum targeting human rotavirus for three days resulted in a modest but significant reduction in the duration of diarrhea and the total amount of stool produced among male infants aged 6–24 months, according to a double-blinded, placebo-controlled study by Mitra et al. (1995). These results are corroborated by another investigation that found that isolated immunoglobulins from hyperimmune cow colostrum had a comparable impact in acute rotavirus infection.
Four independent studies describe rotavirus-diarrhea treatment with hyperimmune colostrum products. Two studies were double-blind, placebo-controlled studies performed in Bangladesh, and another two were controlled studies in Europe. Three of the studies showed significant clinical effects, including a reduction in the duration of diarrhea and stool frequency.
In human challenge trials, specially formulated bovine colostral-IgG preparations provided protection against some enterotoxigenic E. coli strains.
One study found that IgG and IgA purified from bovine colostrum containing human rotavirus antibodies did not protect against rotavirus infection, suggesting that other immunoreactive components other than immunoglobulins in bovine colostrum may be involved in immune protection.
Evidence assessment: This is one of the better-studied areas of bovine IgG application. Multiple controlled and double-blind, placebo-controlled trials in children exist, particularly for hyperimmune preparations. However, most trials are small and used diverse products, making direct comparison difficult. Findings are promising but not definitive across all pathogen types and formulations.
Recent studies of SBI in human beings have yielded results of efficacy, and the product has been shown in multiple clinical reports to manage effectively the chronic loose and frequent stools found in conditions such as IBS-D and HIV-associated enteropathy, as well as to improve nutritional outcomes in pediatric malnutrition.
Among adults, preliminary studies show promising results of SBI in the management of HIV enteropathy in addition to diarrhea-predominant irritable bowel syndrome. Collectively, there is evidence to support the theory that ingestion of oral immunoglobulins such as SBI could reduce the risk of bacterial translocation in patients with cirrhosis, namely by neutralizing bacterial antigen in the intestine, reducing intestinal inflammation, and decreasing permeability of the gut barrier.
Evidence assessment: Evidence for IBD specifically is limited primarily to case reports and very small open-label series. Larger, well-powered randomized trials are needed.
Bovine colostrum has been used as a dietary supplement to treat diarrhea, infections, and colitis, and to improve athletic performance. Dosages up to 60 g/day for up to 12 weeks have been used in clinical trials evaluating use for athletic enhancement. In trials using bovine colostrum for exercise-induced GI permeability, dosages of 20 g/day for 14 days, or 1 g/day for 20 days have been used; in one trial, a dosage of 1.7 g/kg/day for 7 days prior to an exercise protocol was used.
Bovine colostrum supplementation at 10 g twice daily for 4 weeks significantly improved neutrophil functional activity compared with controls (P<0.05) but not any of the other immune parameters tested. There is increasing evidence of efficacy in boosting the immune system, preventing upper respiratory tract infection, reducing GI permeability, and enhancing athletic performance, although data are conflicting and are based on small sample sizes and studies of limited quality.
Evidence assessment: Evidence in this area is mixed. Effects related to gastrointestinal permeability during exercise show some consistency across small trials, but broader claims for athletic performance enhancement remain inadequately supported. Studies are generally underpowered and heterogeneous in design and product used.
A large number of studies in infants and adults have shown that bovine IgG (or colostrum as a rich source thereof) can prevent gastrointestinal tract infections, upper respiratory tract infections, and LPS-induced inflammation.
Studies have shown that providing certain bovine colostrum supplementation in children can significantly improve immunity and reduce the incidence of diarrhea and upper respiratory tract infections (URTI), related to the abundant immunoreactive components provided by bovine colostrum.
Evidence assessment: Preliminary and positive signals exist, but most individual trials are small and use heterogeneous product formulations. Systematic reviews find consistent trends in some populations, but the field lacks large, well-designed, definitive confirmatory trials.
SBI prevents translocation and inflammation via direct binding of microbial components and has displayed potential benefits through gut microbiome modulation. SBI digestion and colonic fermentation were investigated using the clinically predictive ex vivo SIFR® technology for 24 human adults, combined with host cells (epithelial/immune Caco-2/THP-1 cells). At human equivalent doses of 2 and 5 g/day, SBI significantly promoted gut barrier integrity more profoundly than a dietary protein control, especially upon LPS-induced inflammation.
Numerous studies have demonstrated that oral administration of plasma- or serum-derived protein concentrates containing high levels of immunoglobulins can improve weight management, normalize gut barrier function, and reduce the severity of enteropathy in animals.
Evidence assessment: Preclinical (animal model) and ex vivo data are strong and mechanistically coherent, but they cannot substitute for large human clinical trials. They are best understood as supportive evidence for plausible mechanisms of action.
Dosages reported in peer-reviewed clinical literature vary significantly depending on indication, product type, and population:
The prescription medical food formulation (EnteraGam) is supplied in individual packets containing 5 grams of SBI, with the following inactive ingredients: dextrose, orange (natural and artificial flavors) and coloring (Yellow #6).
Bovine colostrum is well tolerated, with minor GI complaints (e.g., nausea, flatulence, diarrhea), unpleasant taste, and skin rash occurring infrequently. The US Food and Drug Administration (FDA) has accepted the safety of hyperimmune milks on the basis that no adverse health effects have been shown in clinical studies.
The safety record of SBI is documented in the adverse event profile from those clinical studies, as well as in more than 22,000 patients that have ingested nearly 3 million doses of the commercial product EnteraGam.
Contraindications other than milk allergy have not been identified for bovine colostrum. Bovine colostrum contains trace amounts of estrogen, so patients with hormone-sensitive cancers should discuss this product with their physicians before consumption. In addition, individuals allergic to dairy products should avoid this product. Adverse effects including allergies and intolerance appear unlikely when bovine colostrum is provided as a supplement within normal nutrition guidelines for infants and children.
In a human study of SBI tolerability and digestion, intact bovine IgG was detected in the feces of volunteers but not serum (n=12), providing evidence that bovine immunoglobulin is not absorbed from the intestinal lumen into the circulation. It is important nonetheless to determine whether intact bovine protein, following oral administration, is capable of crossing the intestinal epithelium into the systemic circulation. Current evidence indicates that bovine IgG acts locally within the gastrointestinal lumen and does not achieve measurable systemic levels in healthy adults.
Information regarding safety and efficacy in pregnancy and lactation is lacking. Clinical data in these populations are insufficient to establish safety, and the topic has not been addressed in large controlled trials.
Evidence from preterm infants has raised serious concerns that processed formula products based on cow's milk can lead to more necrotizing enterocolitis (NEC), late-onset sepsis, food intolerance, allergies, and food-protein-induced enterocolitis syndrome (FPIES) in infants fed formula alone, or in combination with human milk. This has led some clinicians to warn against use of bovine-milk products for all sensitive hospitalized infants. It is unknown if the apparent adverse effects relate to their bovine origin, the industrial processing steps, or additions of vegetable products as part of commercial formula production. Exclusive bovine colostrum feeding is not recommended for infants because of nutritional imbalances relative to human milk.
No well-documented drug interactions have been identified for bovine colostrum-derived IgG preparations in the available clinical literature. As a protein-based nutrient acting primarily within the gastrointestinal lumen, pharmacokinetic interactions with systemically absorbed drugs are not expected based on the available evidence, but this has not been formally studied.
Immunoglobulins and other bioactive factors in bovine colostrum may work in synergy, making it critical to preserve bioactivity with gentle processing and pasteurization methods. Formula-fed infants receive minimal amounts of immunomodulatory proteins and immunoglobulins because processing technologies and heat treatment for microbiological safety normally denature these proteins. This is a meaningful limitation when evaluating the comparability of different commercial preparations.
In the United States, bovine colostrum-derived IgG products are sold as dietary supplements under the Dietary Supplement Health and Education Act (DSHEA). Serum-derived bovine immunoglobulin/protein isolate in its prescription form (EnteraGam) is regulated as a medical food under FDA oversight. SBI is an orally administered prescription medical food manufactured in accordance with Good Manufacturing Practices and FDA guidelines for medical food ingredients. It is indicated for the nutritional management of a patient with enteropathy who, because of therapeutic or chronic medical needs, has limited or impaired capacity to ingest, digest, absorb, or metabolize ordinary foodstuffs or certain nutrients.
Several clinical trials suggest that various bovine colostrum preparations may be helpful to treat or prevent diarrhea, but additional studies are needed. Similarly, more studies are needed on the conditions under which it may confer immune function benefits.
There is increasing evidence of efficacy in boosting the immune system, preventing upper respiratory tract infection, reducing GI permeability, and enhancing athletic performance, although data are conflicting and are based on small sample sizes and studies of limited quality. Standardization of commercial bovine colostrum products is difficult because antibody content varies widely.
Recent trials in humans provide preliminary evidence that serum-derived bovine immunoglobulin/protein isolate is safe and improves symptoms, nutritional status, and various biomarkers associated with enteropathy in patients with HIV infection or diarrhea-predominant irritable bowel syndrome. Nonetheless, the overall body of clinical evidence in humans remains limited by small trial sizes, open-label designs, product heterogeneity, and a lack of large-scale, double-blind, placebo-controlled trials across most indication areas.
Health conditions that Immunoglobin G may help support.
Clinical trials of SBI (high-IgG bovine serum protein) in IBS-D patients show consistent improvements in abdominal pain and discomfort. At 10 g/day, statistically significant within-group reductions in abdominal pain (p<0.01) and bloating (p<0.05) have been documented. A case series further confirms reductions in abdominal distention and incontinence.
A randomized, double-blind, placebo-controlled pilot study in children aged 8–18 with diarrhea-predominant IBS found that SBI at 10 g/day was safe and improved GI symptoms including stool number and abdominal pain. A pediatric case report also documented clinical and pathological remission of pediatric ulcerative colitis with SBI added to standard treatment.
SBI has been shown to support gut-associated immune reconstitution in children and adults through increased mucosal CD4+ T-cell counts and reduced inflammatory markers. Pediatric clinical studies of SBI in IBS confirm it is safe and well-tolerated in children, with immune-modulating properties linked to IgG-mediated antigen binding in the gut.
Oral SBI has been shown to reduce systemic inflammatory markers in humans with chronic gut-driven inflammation. In a 103-patient randomized double-blind trial, SBI significantly lowered IL-6 (p=0.002) over 24 weeks. Ex vivo human studies confirm SBI specifically lowers TNF-α and CXCL10 in colonic tissue models.
SBI has been studied in ulcerative colitis patients as an adjunct to standard regimens, with a pediatric case report documenting clinical and pathological remission. Preclinical mouse models show oral SBI attenuates DSS-induced colitis inflammation. An ex vivo human sample study confirmed SBI reduces key colonic inflammatory cytokines.
In retrospective clinical studies, SBI (bovine serum IgG) has been used as adjunct nutritional support in Crohn's disease patients unresponsive to standard therapy, with reported symptom improvements. Animal colitis models also demonstrate SBI attenuates E. coli-associated colonic inflammation.
Serum-derived bovine IgG (SBI) has been evaluated in multiple clinical studies for managing chronic diarrhea across several conditions. A pilot study in 30 IBS-D patients showed statistically significant reductions in loose stools, abdominal pain, and urgency at 5–10 g/day. SBI is also registered as a medical food for diarrhea management in IBS-D and HIV-associated enteropathy.
SBI has shown prebiotic-like effects on gut microbiota composition in human IBS/IBD patients and in ex vivo models. A 2024 PMC study found 30 days of SBI significantly increased species diversity, raised Bifidobacterium, and decreased Proteobacteria. Ex vivo work confirms SBI enhances SCFA production via specific gut microbes.
SBI (serum-derived bovine IgG) has clinical evidence in diarrhea-predominant IBS (IBS-D). Multiple studies, including a pilot RCT and retrospective chart reviews, demonstrate significant reductions in abdominal pain, loose stools, bloating, and urgency. Mechanistic studies from Mayo Clinic indicate SBI improves bowel function and alters duodenal microbiota composition.
SBI has been evaluated as adjunct nutritional therapy in IBD patients refractory to standard treatment. Retrospective chart reviews show symptom improvement in patients with Crohn's disease and ulcerative colitis. A 2024 PMC study also confirmed that SBI alters gut microbiota diversity in IBD patients in a favorable direction.
SBI (serum-derived bovine IgG) has demonstrated significant reduction of intestinal permeability biomarkers in human clinical studies. A randomized double-blind HIV study showed SBI significantly lowered circulating zonulin and I-FABP — established markers of gut barrier disruption. Ex vivo models confirm SBI promotes gut barrier integrity more profoundly than dietary protein controls.
SBI has shown evidence of supporting mucosal immune reconstitution after gut-damaging illness, particularly HIV enteropathy, where it significantly increased CD4+ T cell counts and improved intestinal absorptive function. Its role in normalizing gut barrier markers after immune-depleting illness is documented in multiple clinical studies.
SBI is clinically used as a medical food for managing chronic diarrhea in SIBO, per the published Wikipedia entry on EnteraGam and retrospective clinical series. Its IgG content binds bacterial antigens, potentially normalizing the microbial environment of the small intestine. Evidence is primarily clinical series and retrospective data rather than RCTs specific to SIBO.
Oral SBI was studied in a randomized pilot trial of mild-to-moderate COVID-19, showing faster resolution of symptoms and a trend toward WHO scale improvement in the SBI arm. IgG in SBI also broadly supports mucosal immunity and CD4+ T cell reconstitution, relevant to systemic viral responses.
Body systems that Immunoglobin G may help support.
Go back